{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:00:20Z","timestamp":1787979620743,"version":"build-2784847793"},"reference-count":29,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P&amp;lt; .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P&amp;lt; .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018342","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:31:36Z","timestamp":1766086296000},"page":"1400-1404","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2642-7160","authenticated-orcid":false,"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[{"name":"2Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman Salim","family":"Akhtar","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Narra","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcello C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarinath","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-9760","authenticated-orcid":false,"given":"Douglas","family":"Lin","sequence":"additional","affiliation":[{"name":"2Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Ho","sequence":"additional","affiliation":[{"name":"2Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"9","key":"2026022411374478500_bib1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11912-024-01563-0","article-title":"Current status on management of primary plasma cell leukemia","volume":"26","author":"Gong","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"2026022411374478500_bib2","doi-asserted-by":"crossref","first-page":"e433520","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"2026022411374478500_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-018-0089-0","article-title":"Integrated DNA\/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay","volume":"8","author":"Intlekofer","year":"2018","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026022411374478500_bib4","doi-asserted-by":"crossref","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"issue":"19","key":"2026022411374478500_bib5","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.18632\/oncotarget.4028","article-title":"Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns","volume":"6","author":"Cifola","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"2026022411374478500_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026022411374478500_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"2026022411374478500_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","article-title":"Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma","volume":"120","author":"Walker","year":"2012","journal-title":"Blood"},{"key":"2026022411374478500_bib9","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"2026022411374478500_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjh.13256","article-title":"The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma","volume":"169","author":"Wei\u00dfbach","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2026022411374478500_bib11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3324\/haematol.2021.278342","article-title":"DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome","volume":"107","author":"Todoerti","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2026022411374478500_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3324\/haematol.2023.283445","article-title":"Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling","volume":"109","author":"Cardona-Benavides","year":"2024","journal-title":"Haematologica"},{"issue":"17","key":"2026022411374478500_bib13","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026022411374478500_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.12920","article-title":"PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform","volume":"166","author":"Hofmann","year":"2014","journal-title":"Br J Haematol"},{"issue":"7339","key":"2026022411374478500_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2026022411374478500_bib16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3324\/haematol.2019.217927","article-title":"Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma","volume":"105","author":"Mikulasova","year":"2020","journal-title":"Haematologica"},{"issue":"17","key":"2026022411374478500_bib17","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026022411374478500_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/PO.20.00503","article-title":"Palbociclib as a novel therapy for low-grade mucinous carcinomatosis peritonei of appendiceal origin","volume":"5","author":"Childers","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"2026022411374478500_bib19","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cncr.32649","article-title":"Targeting fusions for improved outcomes in oncology treatment","volume":"126","author":"Nikanjam","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"2026022411374478500_bib20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1535-7163.MCT-20-0861","article-title":"BRAF V600E\/V600K mutations versus nonstandard alterations: prognostic implications and therapeutic outcomes","volume":"20","author":"Nikanjam","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2026022411374478500_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s44276-024-00086-2","article-title":"Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors","volume":"2","author":"\u00d6zg\u00fc","year":"2024","journal-title":"BJC Rep"},{"issue":"14","key":"2026022411374478500_bib22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A phase 2 clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026022411374478500_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/pgs.15.174","article-title":"Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment","volume":"17","author":"Cheung","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"10","key":"2026022411374478500_bib24","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/1078-0432.CCR-20-3761","article-title":"Concomitant MEK and cyclin gene alterations: implications for response to targeted therapeutics","volume":"27","author":"Kato","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026022411374478500_bib25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"2026022411374478500_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2026022411374478500_bib27","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.medj.2024.11.003","article-title":"If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide","volume":"6","author":"Adashek","year":"2025","journal-title":"Med"},{"issue":"23","key":"2026022411374478500_bib28","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2025016966","article-title":"Safety and efficacy of BCMA directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia","volume":"9","author":"Galarza Fortuna","year":"2025","journal-title":"Blood Adv"},{"issue":"19","key":"2026022411374478500_bib29","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1182\/bloodadvances.2025016695","article-title":"The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia","volume":"9","author":"Shrestha","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1400\/2504277\/blooda_adv-2025-018342-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1400\/2504277\/blooda_adv-2025-018342-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:37:50Z","timestamp":1771951070000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1400\/557389\/Plasma-cell-leukemia-genomic-features-and-their"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018342","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,17]]}}}